Covestor Ltd Has $29,000 Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Covestor Ltd lifted its stake in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 23,050.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 926 shares of the company’s stock after buying an additional 922 shares during the period. Covestor Ltd’s holdings in IDEAYA Biosciences were worth $29,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of IDYA. SG Americas Securities LLC acquired a new stake in IDEAYA Biosciences in the first quarter valued at $101,000. Oppenheimer & Co. Inc. acquired a new stake in IDEAYA Biosciences during the 1st quarter worth about $217,000. Swiss National Bank grew its holdings in IDEAYA Biosciences by 30.9% during the 1st quarter. Swiss National Bank now owns 111,400 shares of the company’s stock worth $4,888,000 after acquiring an additional 26,300 shares during the period. ProShare Advisors LLC grew its holdings in IDEAYA Biosciences by 21.1% during the 1st quarter. ProShare Advisors LLC now owns 17,047 shares of the company’s stock worth $748,000 after acquiring an additional 2,966 shares during the period. Finally, Orion Portfolio Solutions LLC acquired a new stake in IDEAYA Biosciences during the 1st quarter worth about $1,431,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on IDYA. Leerink Partners downgraded IDEAYA Biosciences from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $41.00 to $27.00 in a report on Tuesday, November 5th. Leerink Partnrs lowered IDEAYA Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 5th. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of IDEAYA Biosciences in a research note on Tuesday, September 24th. Wedbush restated an “outperform” rating and issued a $52.00 target price on shares of IDEAYA Biosciences in a research note on Monday, November 4th. Finally, Cantor Fitzgerald began coverage on IDEAYA Biosciences in a research report on Tuesday, October 15th. They set an “overweight” rating for the company. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $53.91.

IDEAYA Biosciences Trading Down 9.6 %

Shares of IDYA opened at $26.64 on Friday. The company has a market cap of $2.30 billion, a PE ratio of -11.74 and a beta of 0.86. The stock has a 50-day moving average price of $31.61 and a 200-day moving average price of $36.46. IDEAYA Biosciences, Inc. has a 12-month low of $26.41 and a 12-month high of $47.74.

IDEAYA Biosciences (NASDAQ:IDYA) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.03. During the same period in the prior year, the company posted ($0.46) EPS. As a group, analysts predict that IDEAYA Biosciences, Inc. will post -2.46 earnings per share for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.